Subretinal transplantation of retinal pigment epithelial cells derived from human embryonic stem cells appears to be well tolerated in patients with dry age-related macular degeneration and geographic atrophy, according to the interim results of a phase 1/2 clinical trial.
Improved visual acuity was achieved in a subgroup of patients with better baseline vision, some of whom underwent cell injection with a new subretinal delivery system (SDS) without vitrectomy or retinotomy.
Christopher D. Riemann, MD, who presented the results at the virtual Association for Research in Vision and
Uncategorized